#Israel #Jerusalem #Scinai #PC111 #Recipharm

Scinai Immunotherapeutics 2025 Financial Results Overview

On April 1, 2026, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical entity engaged in both R&D and CDMO (Contract Development and Manufacturing Organization) operations, announced its financial achievements for the year concluding on December 31, 2025. This financial recap reflects not only impressive growth but also major strategic steps taken within the company.

Financial Highlights 2025

In 2025, Scinai's CDMO revenues experienced a remarkable increase, doubling from the previous year to reach $1.3 million. This surge indicates a strong commercial traction, signaling that their development and manufacturing programs are yielding competitive results in the biotechnology marketplace.

One of the key developments was the acquisition of Recipharm Israel, a strategic move aimed at expanding Scinai’s manufacturing capabilities. Through this collaboration, the company has broadened its service offerings, enabling it to support a wider range of customer programs from initial development stages to commercial production. This innovative model enhances Scinai’s global reach while ensuring a seamless transition across various stages of drug development.

Scinai has positioned its lead compound, PC111, as a pivotal asset in its pipeline. This fully human monoclonal antibody targets inflammatory pathways and holds promise for treating severe dermatological conditions. Furthermore, Scinai has actively sought additional funding to support the development of PC111 through non-dilutive channels such as the FENG grant.

Operational Insights

Operating expenses for R&D in 2025 were $2.4 million, a significant decrease from $5.5 million in 2024, mainly due to reduced employee and facility cost allocations. Despite facing a net loss of $8.3 million, a shift from the previous year’s profit of $4.8 million, the management remains optimistic about the strategic direction of the company.

Scinai has also emphasized shifting its funding approach towards non-dilutive sources. By focusing on securing grants, the company aims to propel its key programs without compromising equity. The effective structure of the FENG grant offers a potential leverage of up to five times the R&D capital, further supporting Scinai’s vision to advance its pipeline.

Acquisition of Recipharm

A pivotal milestone for Scinai was the acquisition of the manufacturing site of Recipharm Israel, finalized in February 2026. This significant acquisition facilitates the expansion of Scinai’s capabilities beyond biologics, allowing entry into the small-molecule development realm. By leveraging Recipharm's global network, Scinai enhances its operational portfolio, positioning itself as an integrated CDMO platform. This strategic collaboration is set to enable Scinai to support various customer programs, enhancing their position across the drug development lifecycle.

Management Insights

Amir Reichman, Scinai's CEO, articulated the company's achievements, noting, “2025 was a year marked by focused execution and refined strategic priorities.” He highlighted the importance of doubling revenues and improving operational efficiencies, emphasizing that the Recipharm acquisition represents a transformative step towards enhancing capabilities and market reach.

Looking forward, Scinai aims to scale its CDMO business while continuing to advance its prominent projects, like PC111 and the NanoAbs platform, all the while leveraging non-dilutive funding mechanisms to maximize impact.

Conclusion

Scinai Immunotherapeutics has evidently set a solid foundation for future success with its doubling revenue figures and strategic acquisitions. As they navigate the complexities of drug development with enhanced capabilities and focus on capital efficiency, the company is well-positioned to impact the biotechnology landscape significantly. Stakeholders can review the complete annual report detailing these developments on their investor relations website at www.scinai.com/investorsrelations.